Page last updated: 2024-08-21

quinazolines and canertinib

quinazolines has been researched along with canertinib in 33 studies

Research

Studies (33)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	17 (51.52)	29.6817
2010's	16 (48.48)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chan, OH; Denny, WA; Elliott, WL; Greis, KD; Lipka, E; Loo, JA; Rewcastle, GW; Reyner, EL; Showalter, HD; Smaill, JB; Vincent, PW	1
Baselga, J; Hammond, LA	1
Lorusso, PM	1
Grünwald, V; Hidalgo, M	1
Chinnaiyan, AM; Ethier, SP; Hanasoge, S; Lawrence, TS; Leopold, WR; Maheshwari, D; Nyati, MK; Rynkiewicz, SD; Sreekumar, A	1
Aunoble, B; Bourhis, J; Rolhion, C; Tortochaux, J	1
Herbst, RS	1
Damon, IK; Kim, M; Kim, SK; Morehead, TJ; Reche, PA; Reinherz, EL; Welsh, RM; Yang, H	1
Lindner, H; Loeffler-Ragg, J; Lukas, P; Sarg, B; Skvortsov, S; Skvortsova, I; Tabernero, J; Zwierzina, H	1
Brose, MS; Flaherty, KT	1
Arteaga, CL; Carpenter, G; Gazdar, AF; Muthuswamy, SK; Narasanna, A; Perez-Torres, M; Wang, SE; Wu, FY; Xiang, B; Yang, S	1
Sequist, LV	1
Breza, N; Keri, G; Orfi, L; Petak, I; Pinter, F; Robert, K; Schwab, R; Varkondi, E	1
Avizienyte, E; Garner, AP; Ward, RA	1
Balk, SP; Didonato, M; Flatauer, L; Gray, NS; Hur, W; Jiang, X; Kim, S; Larson, B; Mason, DE; Nagle, A; Peters, EC; Suzuki, M; Valente, D; Velentza, A; Warmuth, M; Zagorska, A; Zhang, J	1
Dilworth, JT; Hancock, CN; Mathieu, P; Mattingly, RR; Reiners, JJ; Tainsky, MA; Wojtkowiak, JW	1
Amir, E; Ocaña, A	1
Belani, CP	1
Milsom, C; Rak, J; Xing, R; Yu, JL	1
Hughes, DP; Richards, KN; Speleman, F; Trevino, J; Van Roy, N; Zage, PE; Zweidler-McKay, PA	1
Biordi, L; Festuccia, C; Ficorella, C; Gravina, GL; Jannini, EA; Marampon, F; Motta, M; Piccolella, M; Tombolini, V	1
Pandiella, A; Sánchez-Martín, M	1
Khurana, V; Minocha, M; Mitra, AK; Pal, D; Qin, B	1
Abagyan, R; Behera, R; Katiyar, S; Kufareva, I; Mensa-Wilmot, K; Ogata, Y; Pollastri, M; Thomas, SM	1
Behera, R; Edwards, P; Guyett, PJ; Karver, CE; Mensa-Wilmot, K; Patel, G; Pollastri, MP; Roncal, NE; Sullenberger, C	1
Behera, R; Mensa-Wilmot, K; Thomas, SM	1
Batra, SK; Ganti, AK; Haridas, D; Lakshmanan, I; Ponnusamy, MP; Rachagani, S; Seshacharyulu, P; Yan, Y	1
Grunt, TW; Gschwantler-Kaulich, D; Kölbl, H; Muhr, D; Singer, CF; Wagner, R	1
Boerner, J; Joiakim, A; Mathieu, PA; Reiners, JJ; Shelp, C	1
Asahi, M; Ide, C; Kanekiyo, K; Nakagawa, T; Nakano, N	1
Althaus, IW; Black, SL; Blaser, A; Bridges, A; Denny, WA; Ellis, PA; Ellis, T; Fakhoury, S; Gonzales, AJ; Harvey, PJ; Hook, K; Lee, H; McCarthy, FO; Palmer, BD; Reed, JE; Rivault, F; Schlosser, K; Sexton, K; Smaill, JB; Spicer, JA; Tecle, H; Thompson, AM; Trachet, E; Winters, RT; Zhu, T	1
Balaji, S; Dayakar, G; Guda, R; Kasula, M; Korra, R; Kumar, G; Myadaraveni, P; Palabindela, R; Yellu, NR	1
Kang, Y; Ma, W; Yang, L; Yang, T; Zhu, M	1

Reviews

10 review(s) available for quinazolines and canertinib

Article	Year
HER-targeted tyrosine-kinase inhibitors. Oncology, 2002, Volume: 63 Suppl 1 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Morpholines; Ovarian Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Receptor, ErbB-2	2002
Phase I studies of ZD1839 in patients with common solid tumors. Seminars in oncology, 2003, Volume: 30, Issue:1 Suppl 1 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Morpholines; Ovarian Neoplasms; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines	2003
Developing inhibitors of the epidermal growth factor receptor for cancer treatment. Journal of the National Cancer Institute, 2003, Jun-18, Volume: 95, Issue:12 Topics: Aminoquinolines; Aniline Compounds; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Drug Design; Drugs, Investigational; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Morpholines; Neoplasms; Organic Chemicals; Panitumumab; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Structure-Activity Relationship	2003
[Targeting of epidermal growth factor receptor and applications in ORL cancer]. Bulletin du cancer, 2003, Volume: 90 Spec No Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Morpholines; Neoplasm Proteins; Otorhinolaryngologic Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines	2003
Review of epidermal growth factor receptor biology. International journal of radiation oncology, biology, physics, 2004, Volume: 59, Issue:2 Suppl Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Morpholines; Neoplasm Proteins; Panitumumab; Quinazolines; Radiation Tolerance; Receptor, ErbB-2	2004
Her-2 targeted therapy: beyond breast cancer and trastuzumab. Current oncology reports, 2006, Volume: 8, Issue:2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Female; Humans; Lapatinib; Morpholines; Neoplasms; Ovarian Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab	2006
Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. The oncologist, 2007, Volume: 12, Issue:3 Topics: Aminoquinolines; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Morpholines; Organic Chemicals; Piperidines; Protein Kinase Inhibitors; Quinazolines; Quinolines	2007
Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directions. Cancer treatment reviews, 2009, Volume: 35, Issue:8 Topics: Afatinib; Aminoquinolines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Forecasting; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Morpholines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Quinolines; Trastuzumab; Up-Regulation	2009
The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors. Cancer investigation, 2010, Volume: 28, Issue:4 Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Morpholines; Mutation; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Quinolines	2010
Modulation of the oncogene-dependent tissue factor expression by kinase suppressor of ras 1. Thrombosis research, 2010, Volume: 126, Issue:1 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Factor VIIa; Genes, ras; Humans; Mice; Mice, SCID; Morpholines; Neoplasms; Oncogenes; Phosphotransferases; Quinazolines; Receptor, ErbB-2; Signal Transduction; Thromboplastin; Trastuzumab; Tyrphostins; Up-Regulation	2010

Other Studies

23 other study(ies) available for quinazolines and canertinib

Article	Year
Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions. Journal of medicinal chemistry, 2000, Apr-06, Volume: 43, Issue:7 Topics: Acrylamides; Animals; Antineoplastic Agents; Biological Transport; Caco-2 Cells; Drug Screening Assays, Antitumor; Enzyme Inhibitors; ErbB Receptors; Humans; Mice; Mice, Nude; Morpholines; Neoplasm Transplantation; Phosphorylation; Pyrimidines; Quinazolines; Receptor, ErbB-2; Solubility; Spectrometry, Mass, Electrospray Ionization; Transplantation, Heterologous; Tumor Cells, Cultured	2000
Radiosensitization by pan ErbB inhibitor CI-1033 in vitro and in vivo. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Jan-15, Volume: 10, Issue:2 Topics: Animals; Antineoplastic Agents; Apoptosis; Bromodeoxyuridine; Cell Line, Tumor; Cell Survival; Coloring Agents; DNA; Dose-Response Relationship, Radiation; ErbB Receptors; Flow Cytometry; G1 Phase; Humans; Immunohistochemistry; In Vitro Techniques; Mice; Mice, Nude; Morpholines; Neoplasm Transplantation; Oligonucleotide Array Sequence Analysis; Precipitin Tests; Protein-Tyrosine Kinases; Quinazolines; Radiation-Sensitizing Agents; Radiation, Ionizing; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA; Time Factors	2004
Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. The Journal of clinical investigation, 2005, Volume: 115, Issue:2 Topics: Animals; Chlorocebus aethiops; DNA; ErbB Receptors; Growth Substances; HeLa Cells; Humans; Male; Mice; Morpholines; Pneumonia; Protein Transport; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-cbl; Quinazolines; Signal Transduction; Smallpox; T-Lymphocytes; Ubiquitin-Protein Ligases; Vaccinia; Vaccinia virus; Variola virus; Vero Cells; Viral Proteins	2005
Irreversible pan-ErbB tyrosine kinase inhibitor CI-1033 induces caspase-independent apoptosis in colorectal cancer DiFi cell line. Apoptosis : an international journal on programmed cell death, 2005, Volume: 10, Issue:5 Topics: Amino Acid Chloromethyl Ketones; Apoptosis; Apoptosis Inducing Factor; Caco-2 Cells; Caspase 3; Caspases; Cathepsin D; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Gefitinib; Genes, Tumor Suppressor; Humans; Morpholines; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Receptor, ErbB-2; Serpins	2005
HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer cell, 2006, Volume: 10, Issue:1 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Mice; Mice, Nude; Models, Biological; Morpholines; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering; Transforming Growth Factor alpha; Trastuzumab; Xenograft Model Antitumor Assays	2006
Biochemical assay-based selectivity profiling of clinically relevant kinase inhibitors on mutant forms of EGF receptor. Journal of receptor and signal transduction research, 2008, Volume: 28, Issue:3 Topics: Aminoquinolines; Aniline Compounds; Biological Assay; Drug Resistance; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Inhibitory Concentration 50; Morpholines; Mutant Proteins; Protein Kinase Inhibitors; Quinazolines; Substrate Specificity; Tyrphostins	2008
Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations. The Biochemical journal, 2008, Oct-15, Volume: 415, Issue:2 Topics: Animals; Cell Line; Cell Proliferation; Cell Survival; Drug Combinations; Drug Resistance; ErbB Receptors; Erlotinib Hydrochloride; Immunoblotting; Immunoprecipitation; Interleukin-3; Lapatinib; Mice; Morpholines; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2	2008
Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase. Bioorganic & medicinal chemistry letters, 2008, Nov-15, Volume: 18, Issue:22 Topics: Animals; Cysteine; ErbB Receptors; Mice; Molecular Structure; Morpholines; Protein-Tyrosine Kinases; Quinazolines; Sequence Homology, Amino Acid	2008
Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033. Cancer biology & therapy, 2008, Volume: 7, Issue:12 Topics: Antineoplastic Agents; Cell Division; Cell Line, Tumor; ErbB Receptors; Gefitinib; Humans; Morpholines; Nerve Sheath Neoplasms; Neurofibromatosis 1; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2	2008
Signaling of ERBB receptor tyrosine kinases promotes neuroblastoma growth in vitro and in vivo. Cancer, 2010, Jul-01, Volume: 116, Issue:13 Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Humans; Mice; Mice, Knockout; Morpholines; Neoplasm Transplantation; Neuroblastoma; Protein Kinase Inhibitors; Quinazolines; Signal Transduction	2010
Antitumor effects of carnertinib in castration resistant prostate cancer models: a comparative study with erlotinib. The Prostate, 2011, Oct-01, Volume: 71, Issue:14 Topics: Androgen Antagonists; Anilides; Animals; Apoptosis; Cell Division; Cell Line; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Epithelial Cells; Erlotinib Hydrochloride; Humans; Male; Mice, Nude; Morpholines; Nitriles; Orchiectomy; Prostate; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Quinazolines; Tosyl Compounds; Xenograft Model Antitumor Assays	2011
Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: therapeutic implications. International journal of cancer, 2012, Jul-01, Volume: 131, Issue:1 Topics: Aminoquinolines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lapatinib; Morpholines; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab	2012
Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib. International journal of pharmaceutics, 2012, Oct-15, Volume: 436, Issue:1-2 Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blood-Brain Barrier; Cell Line; Dogs; Erlotinib Hydrochloride; Indazoles; Male; Mice; Morpholines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Sulfonamides	2012
Lapatinib-binding protein kinases in the African trypanosome: identification of cellular targets for kinase-directed chemical scaffolds. PloS one, 2013, Volume: 8, Issue:2 Topics: Adenosine Triphosphate; Amino Acid Sequence; Chromatography, Affinity; ErbB Receptors; HeLa Cells; Humans; Lapatinib; Ligands; Models, Molecular; Molecular Sequence Data; Molecular Targeted Therapy; Morpholines; NAD; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Purines; Quinazolines; Structural Homology, Protein; Trypanosoma brucei brucei	2013
Kinase scaffold repurposing for neglected disease drug discovery: discovery of an efficacious, lapatinib-derived lead compound for trypanosomiasis. Journal of medicinal chemistry, 2013, May-23, Volume: 56, Issue:10 Topics: Animals; Cell Cycle; Cell Line, Tumor; Cell Survival; Coloring Agents; Drug Design; Drug Discovery; ErbB Receptors; Humans; Indicators and Reagents; Lapatinib; Morpholines; Neglected Diseases; Phosphotransferases; Quinazolines; Structure-Activity Relationship; Tetrazolium Salts; Thiazoles; Trypanocidal Agents; Trypanosoma brucei brucei; Trypanosomiasis, African	2013
New chemical scaffolds for human african trypanosomiasis lead discovery from a screen of tyrosine kinase inhibitor drugs. Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:4 Topics: Animals; Axitinib; Benzamides; Erlotinib Hydrochloride; Female; HeLa Cells; Humans; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lapatinib; Mice; Morpholines; Piperazines; Protein Kinase Inhibitors; Purines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib; Trypanosomiasis, African	2014
Targeting EGF-receptor(s) - STAT1 axis attenuates tumor growth and metastasis through downregulation of MUC4 mucin in human pancreatic cancer. Oncotarget, 2015, Mar-10, Volume: 6, Issue:7 Topics: Afatinib; Animals; Apoptosis; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Movement; Cell Proliferation; ErbB Receptors; Female; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Mice; Mice, Nude; Morpholines; Mucin-4; Pancreatic Neoplasms; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; STAT1 Transcription Factor; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2015
HER Specific TKIs Exert Their Antineoplastic Effects on Breast Cancer Cell Lines through the Involvement of STAT5 and JNK. PloS one, 2016, Volume: 11, Issue:1 Topics: Afatinib; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Humans; Inhibitory Concentration 50; JNK Mitogen-Activated Protein Kinases; Lapatinib; MAP Kinase Signaling System; Morpholines; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Quinazolines; STAT5 Transcription Factor	2016
Epidermal Growth Factor Receptor Kinase Inhibitors Synergize with TCDD to Induce CYP1A1/1A2 in Human Breast Epithelial MCF10A Cells. Drug metabolism and disposition: the biological fate of chemicals, 2016, Volume: 44, Issue:5 Topics: Benzamides; Breast; Cell Line; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2; Drug Synergism; Epithelial Cells; ErbB Receptors; Gefitinib; Humans; MAP Kinase Kinase 1; Morpholines; Polychlorinated Dibenzodioxins; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; Tyrphostins	2016
NTAK/neuregulin-2 secreted by astrocytes promotes survival and neurite outgrowth of neurons via ErbB3. Neuroscience letters, 2016, 05-27, Volume: 622 Topics: Animals; Astrocytes; Cell Survival; Culture Media, Conditioned; Morpholines; Nerve Growth Factors; Neurites; Neurons; Phosphorylation; Quinazolines; Rats, Sprague-Dawley; Receptor, ErbB-3; Receptor, ErbB-4	2016
Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family. Journal of medicinal chemistry, 2016, 09-08, Volume: 59, Issue:17 Topics: Administration, Oral; Animals; Antineoplastic Agents; Dogs; ErbB Receptors; Heterografts; Humans; Injections, Intravenous; Macaca fascicularis; Male; Mice, Nude; Morpholines; Neoplasm Transplantation; Phosphorylation; Pyridines; Pyrimidines; Quinazolines; Quinazolinones; Rats, Sprague-Dawley; Stereoisomerism; Structure-Activity Relationship	2016
EGFR, HER2 target based molecular docking analysis, in vitro screening of 2, 4, 5-trisubstituted imidazole derivatives as potential anti-oxidant and cytotoxic agents. Journal of photochemistry and photobiology. B, Biology, 2017, Volume: 176 Topics: A549 Cells; Antineoplastic Agents; Antioxidants; Binding Sites; Cell Line, Tumor; Cell Survival; Drug Design; ErbB Receptors; Gefitinib; HEK293 Cells; HeLa Cells; Humans; Hydrogen Bonding; Imidazoles; Molecular Docking Simulation; Morpholines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Receptor, ErbB-2; Structure-Activity Relationship; Thermodynamics	2017
Investigation of the binding characteristics between ligands and epidermal growth factor receptor by cell membrane chromatography. Journal of molecular recognition : JMR, 2018, Volume: 31, Issue:6 Topics: Afatinib; Cell Membrane; Chromatography; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; HEK293 Cells; Humans; Ligands; Molecular Docking Simulation; Morpholines; Piperidines; Protein Binding; Protein Kinase Inhibitors; Quinazolines	2018